AltruBio lands up to $225M after shift to immune drug research
BioPharma Drive: Drug Pricing
MAY 21, 2024
Since pivoting from oncology, the startup has raised close to $300 million and advanced an ulcerative colitis drug into mid-stage testing.
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
BioPharma Drive: Drug Pricing
MAY 21, 2024
Since pivoting from oncology, the startup has raised close to $300 million and advanced an ulcerative colitis drug into mid-stage testing.
BioPharma Drive: Drug Pricing
DECEMBER 12, 2023
Just before clearing Pfizer’s buyout of Seagen, the regulator threatened to block Sanofi’s licensing deal with Maze Therapeutics, a challenge the biotech called ‘‘unprecedented.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioPharma Drive: Drug Pricing
MARCH 1, 2024
Reeling from a difficult year financially, the pharma unveiled a new oncology division it says will produce eight billion-dollar medicines by 2030.
BioPharma Drive: Drug Pricing
APRIL 22, 2024
A new initiative backed by Takeda, Astellas and Sumitomo Mitsui Banking aims to combat a decade-long decline in drug R&D productivity in Japan.
BioPharma Drive: Drug Pricing
AUGUST 22, 2023
Billing itself as both a scientific and investment partner, Foundery aims to provide research grants and drug development support to researchers developing new immunotherapies.
BioPharma Drive: Drug Pricing
MARCH 1, 2024
The cash will be used to advance development of FOG-001, the company’s lead drug that’s now being tested in an early-stage trial for solid tumors.
BioPharma Drive: Drug Pricing
SEPTEMBER 25, 2024
The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound.
BioPharma Drive: Drug Pricing
SEPTEMBER 7, 2023
The Series B round makes Mariana one of the best funded private companies in a growing group of biotechs working on new radiopharmaceutical therapies.
BioPharma Drive: Drug Pricing
JUNE 18, 2024
Belharra will use its chemoproteomics technology to identify immune drugs for Sanofi. Elsewhere, Regenxbio mapped a regulatory path and Taysha shared updated results for its Rett treatment.
BioPharma Drive: Drug Pricing
JANUARY 12, 2024
Arena BioWorks, which will be led by Harvard University scientist Stuart Schreiber, seeks to blend academic and venture capital drug research models.
BioPharma Drive: Drug Pricing
DECEMBER 7, 2023
The funding is indicative of investor interest in an area of drug research that involves at least a dozen startups and multiple publicly traded companies.
BioPharma Drive: Drug Pricing
DECEMBER 13, 2023
The company is now expecting to save $4 billion by the end of 2024, with a majority of the spending cuts coming from drug research and development.
BioPharma Drive: Drug Pricing
JULY 5, 2023
The deal enables Sarepta to quickly cash in on the clearance of Elevidys, with $102 million in new funds to help bankroll its drug research.
Drugs.com
OCTOBER 24, 2023
23, 2023 -- New research suggests a link between middle school students being disciplined for marijuana use and legalization of recreational weed, particularly when schools are close to dispensaries that sell the drug. Researchers. MONDAY, Oct.
BioPharma Drive: Drug Pricing
JULY 11, 2023
RA Capital led a Series B financing round that drew participation from more than a dozen blue-chip venture backers, including new investors Goldman Sachs and Vertex Ventures.
BioPharma Drive: Drug Pricing
AUGUST 15, 2023
More than a dozen startups have joined a few publicly traded biotechs and larger pharmaceutical firms in what’s become one of the most competitive areas in drug research.
BioPharma Drive: Drug Pricing
AUGUST 16, 2024
Some industry watchers described the level of price discounts announced by Medicare as a "relief," though they warned of bigger future implications for drug research.
BioPharma Drive: Drug Pricing
MARCH 12, 2024
Allogene’s partnership with Arbor is designed to help the company stand out in what’s quickly become one of the industry’s hottest areas of drug research.
Chemical Biology and Drug Design
JULY 5, 2024
Abstract Intestinal absorption of compounds is significant in drug research and development. The QSPR model accurately predicted the intestinal absorption of molecules, and the computer simulation found the mechanism of molecular structure affecting intestinal absorption.
BioPharma Drive: Drug Pricing
OCTOBER 22, 2024
A medicine the pharma acquired in a $430 million buyout of Visterra in 2018 succeeded in a Phase 3 trial in IgA nephropathy, a crowded corner of drug research.
BioPharma Drive: Drug Pricing
NOVEMBER 22, 2024
Despite plans to shutter 1,200 stores, the company’s chief clinical trials officer said the pharmacy giant remains committed to aiding drug research.
BioPharma Drive: Drug Pricing
JUNE 14, 2023
The alliance is Astellas’ second recent partnership involving protein degraders, an emerging area of drug research the company has made a focus in recent years.
BioPharma Drive: Drug Pricing
FEBRUARY 28, 2024
Well-known scientist and biotech entrepreneur Robert Langer is helping Lindus Health address longstanding challenges in contract drug research.
Cytel
JUNE 19, 2024
Historically, many drugs have been prescribed to children even though this patient population have largely been excluded from clinical trials. There is an obvious logic. If medicines are to be used in children, they need to be studied in pediatric populations to ensure they are safe and effective.
Drug Channels
MARCH 5, 2024
The potential effect of the IRA on manufacturers’ new drug research and development strategies is beyond the scope of this webinar. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Pharmacies and Pharmacy Benefit Managers. Read on for full details on pricing and registration.
BioPharma Drive: Drug Pricing
JULY 26, 2023
The startup, which initially aims to make cancer medicines, claims to have a new twist on covalent drug research.
BioPharma Drive: Drug Pricing
JULY 6, 2023
The contract services provider, which secured the deal through a reportedly competitive process, expects CorEvitas to expand its drug research business.
Crown Bioscience
AUGUST 2, 2021
Continue reading to learn more about IMIDs and some of the challenges facing the field, and to review some in vivo preclinical models that can be used to guide IMID drug research and development.
Vial
MAY 20, 2024
In this article, we will define preclinical and clinical CROs, as well as highlight the unique needs and challenges of these organizations in their respective stages of drug research. What is a Pre-Clinical CRO? The global preclinical CRO market was estimated to be valued at US$5.7 billion in 2022 and is projected to reach US$10.2
DrugBank
SEPTEMBER 12, 2024
Data Exploration If you’re venturing into a new area of drug research, the Data Dictionary helps you identify relevant data fields and understand their context. Together, let’s leverage the power of well-defined, transparent data to accelerate innovation in drug research and development.
DrugBank
AUGUST 20, 2024
The Power of Drug Repurposing Explore the immense potential of drug repurposing as a strategy for targeting undruggable targets. By identifying new uses for existing drugs, researchers can significantly reduce development time and costs.
Conversations in Drug Development Trends
FEBRUARY 21, 2024
As a result, we ensure collection of all urine and fecal samples over a period ranging between five to seven days, modifying the participant diet if needed.
DrugBank
OCTOBER 30, 2024
This lets you focus on what matters most: driving meaningful results in drug research and development. Your Need for Accessible, High-Quality Data—Solved Pharmaceutical research and healthcare innovation demand timely access to comprehensive, up-to-date data.
Drug Target Review
OCTOBER 26, 2023
They can accelerate various aspects of drug research and development, providing novel opportunities for faster and more effective solutions to health challenges. Much like models such as ChatGPT that showcase AI’s vast capabilities in natural language processing and knowledge understanding.
Common Sense for Drug Policy Blog
NOVEMBER 26, 2024
The tusi phenomenon also has the potential to complicate drug research. A task force in California has already seized 4.4 of pink powder containing ketamine and despropionyl fentanyl ( 24 ), but this is a fentanyl precursor, which is thought to be relatively inactive ( 25 ).
Drug Target Review
SEPTEMBER 21, 2023
She spent one year as a research assistant, focusing on NTDs and one year as a teaching assistant, focusing on Pharmacology. She is currently a lab technician and research assistant at Hallmark Medicals, where she assists in the conducting of Assisted Reproductive Technologies (ARTs) and drug research.
DrugBank
MAY 15, 2024
The binding pockets on KRAS are shallow and polar , not ideal for the kinds of interactions needed for strong, effective drug binding. In fact, it's one of the most exciting areas in drug research today. One approach is to look beyond the traditional drug molecule.
ACTO
SEPTEMBER 11, 2024
“The life sciences industry is actively looking for new ways to leverage AI to bring drugs to market faster to patients waiting in need,” said Parth Khanna, CEO of ACTO. Current solutions are almost exclusively focused on marketing, HCP targeting, workflow automation, and performance insight.
Advarra
AUGUST 16, 2022
The law established the Office of Orphan Products Development , providing financial incentives for pharmaceutical companies to develop orphan drugs and making it more viable to invest in orphan drug research and development. The impact was clear: Between 1983 and 2020, FDA approved 599 orphan drugs.
The Pharma Data
APRIL 24, 2021
Further, the EDCTP granted EUR 10 million over five years to the West African Network for Clinical Trials of Antimalarial Drugs , a collaboration between antimalarial drug researchers in Africa and Europe from 10 academic institutions, Novartis and MMV. The EDCTP grant of EUR 21.9
DrugBank
MARCH 22, 2024
These data sources are known for being highly referenced and usable for specific research activities; further yet, a number of recognizable open sources, along with their identifiers, are considered industry standard resources.
The Pharma Data
NOVEMBER 10, 2020
Liu mentioned that he will utilize his knowledge, past experience and worldwide network to lead Innovent into the new decade with even better achievement and grow the company into a truly global first class biopharmaceutical company.
The Pharma Data
MAY 19, 2023
Yancopoulos Innovator Award , named in honor of the pioneering drug researcher and Regeneron co-founder, President and Chief Scientific Officer, for finding an efficient way to identify certain exoplanets that orbit very closely around their stars. Kaitlyn Wang won first place and received the $75,000 George D.
NIH Director's Blog: Drug Development
FEBRUARY 16, 2021
ACTIV was founded last April to accelerate drug research that typically requires more than a decade of clinical ups and downs to develop a safe, effective therapy. And ACTIV has indeed moved at unprecedented speed since its launch.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content